RT Journal Article
SR Electronic
T1 Osteosarcoma: novel prognostic biomarkers using circulating and cell-free tumour DNA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.12.21267579
DO 10.1101/2021.12.12.21267579
A1 Lyskjær, Iben
A1 Kara, Neesha
A1 De Noon, Solange
A1 Davies, Christopher
A1 Rocha, Ana Maia
A1 Strobl, Anna-Christina
A1 Usher, Inga
A1 Gerrand, Craig
A1 Strauss, Sandra J
A1 Schrimpf, Daniel
A1 Deimling, Andreas von
A1 Beck, Stephan
A1 Flanagan, Adrienne M
YR 2021
UL http://medrxiv.org/content/early/2021/12/14/2021.12.12.21267579.abstract
AB Osteosarcoma (OS) is the most common primary bone tumour in children and adolescents. Despite treatment with curative-intent, many patients die of this disease. Biomarkers for assessment of disease burden and prognoses for osteosarcoma are not available. Circulating-free (cfDNA) and -tumour DNA (ctDNA) are promising biomarkers for disease surveillance in several major cancer types, however only two such studies are reported for OS. In this combined discovery and validation study, we identified four novel methylation-based biomarkers in 171 OS tumours (test set) and comprehensively validated our findings in silico in two independent osteosarcoma sample datasets (n= 162, n=107) and experimentally using digital droplet PCR (ddPCR, n=20 OS tumours). Custom ddPCR assays for these biomarkers were able to detect ctDNA in 40% of pre-operative plasma samples (n=72). ctDNA was detected in 5/17 (29%) post-operative plasma samples from patients who experienced a subsequent relapse post-operatively. Both cfDNA levels and ctDNA detection independently correlated with overall survival, p=0.0015, p=0.0096, respectively. Combining both assays increased the prognostic value of the data. Our findings illustrate the utility of mutation-independent methylation-based markers, broadly applicable ctDNA assays for tumour surveillance and prognostication. This study lays the foundation for multi-institutional collaborative studies to explore the utility of plasma-derived biomarkers for predicting clinical outcome of OS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was received from the Tom Prince Cancer Trust, The Rosetrees and Stoneygate Trusts (M46-F1) and the Bone Cancer Research Trust (BRCT: 6519). IL is supported by the Lundbeck Foundation (R303-2018-3018) and previously by the Tom Prince Cancer Trust. NK was funded by Imperial College London. SB acknowledges support from the Wellcome Trust (WT-218274/Z/19/Z). The study was also supported by the National Institute for Health Research, UCL Genomics and Genome Engineering, UCL Great Ormond Street Institute of Child Health and Pathology Core facilities, the Cancer Research UK University College London Experimental Cancer Medicine Centre, and the RNOH Research and Development Department. AMR and CD was supported by the Tom Prince Cancer Trust. SJS was supported by the National Institute for Health Research, the University College London Hospitals Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Royal National Orthopaedic Hospital (RNOH) Biobank is approved by the National Research Ethics Committee of the Health Research Committee (reference: Integrated Research Application System (IRAS) project identifier: 272816). This study was approved by the National Research Ethics Committee approved UCL/UCLH Biobank Ethics Committee (project no: EC17.14).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesl data produced in the present study are available upon reasonable request to the authors. https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9875/